Skip to main content
SpringerLink
Log in

Strategy, Yield and Risks of Controlling Plasma Lipids in the Primary Prevention of Coronary Heart Disease

  • Chapter
Book cover Drugs Affecting Lipid Metabolism VIII

  • 69 Accesses

Abstract

Reduction of plasma cholesterol and cholesterol-containing lipoproteins, or an increase in high density lipoproteins, is widely accepted as the desired goal for the whole population. It is time that a more critical appraisal is made of this aim in terms of the likely yield and practicability of such a policy.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. I. Holme, S. C. Enger, A. Helgeland, I. Hjermann, Paul Leren, P. G. Lund-Larson, L. A. Solberg, and J. P. Strong, Risk factors and raised atherosclerotic lesions in coronary and cerebral arteries, Statistical analysis from the Oslo Study, Arteriosclerosis 1: 250 – 256 (1981).

    Article  PubMed  CAS  Google Scholar 

  2. The Pooling Project Research Group, Relationship of blood pressure serum cholesterol, smoking habit, relative weight and ECG abnormalities to incidence of major coronary events, Final report of the Pooling Project, J. Chron. Dis. 31: 201 – 306 (1978).

    Article  Google Scholar 

  3. G. Rose, P. J. S. Hamilton, H. Keen, D. D. Reed, P. McCartney, and R. J. Jarrett, Myocardial ischaemia, risk factors and death from coronary heart disease, Lancet 1: 105 – 109 (1977).

    Article  PubMed  CAS  Google Scholar 

  4. U. Goldbourt and J. H. Medalie, Lipoprotein cholesterol and the incidence of coronary heart disease - the Israeli Ischaemic Heart Disease Study, AMA. J. Epidemiol. 109: 296 – 307 (1975).

    Google Scholar 

  5. L. E. Bottiger and L. A. Carlson, Risk factors for ischaemic vascular death from men in the Stockholm Prospective Study, Atherosclerosis 36: 389 – 408 (1980).

    Article  Google Scholar 

  6. W. P. Castelli, R. D. Abbott, and P. M. McNamara, Summary estimates of cholesterol used to predict coronary heart disease, Circulation 67: 730 – 734 (1983).

    Article  PubMed  CAS  Google Scholar 

  7. F. H. Epstein, in: “Prevention and Treatment of Coronary Heart Disease and its Complications”, Excerpta Medica, Amsterdam, pp. 1–11 (1980).

    Google Scholar 

  8. M. F. Oliver, The optimum serum cholesterol, Lancet 2: 655 (1982).

    Article  Google Scholar 

  9. M. F. Oliver, Should we not forget about mass control of coronary risk factors? Lancet 2: 37 – 38 (1983).

    Article  PubMed  CAS  Google Scholar 

  10. S. Dayton, M. L. Pearce, S. Hashimoto, W. J. Dixon, and U. Tomiyasu, A controlled clinical trial of a diet high in unsaturated fat in preventing complications in atherosclerosis, Circulation 39,40; Suppl. 2: 1 – 63 (1969).

    Google Scholar 

  11. O. Turpeinen, M. J. Karvonen, M. Pekkarinen, M. Miettinen, R. Elosuo, and E. Paavilainen, Dietary prevention of coronary heart disease, The Finnish Mental Hospital Study, Int. J. Epidemiol. 8: 99 – 118 (1979).

    Article  PubMed  CAS  Google Scholar 

  12. Report from the Committee of Principal Investigators, A cooperative trial in the primary prevention of ischaemic heart disease using clofibrate, Brit. Heart J. 10: 1069 – 1118 (1978).

    Google Scholar 

  13. P. Puska, J. Tuomilehto, J. Salonen, L. Neittaaumaki, J. Maki, J. Virtamo, A. Nissinen, K. Koskela, and T. Takalo, Changes in coronary risk factors during comprehensive five-year community programme to control cardiovascular diseases (North Karelia Project), Brit. Med. J. 4: 1173 – 1178 (1979).

    Article  Google Scholar 

  14. J. T. Salonen, P. Puska, and H. Mustaniemi, Changes in morbidity and mortality during comprehensive community programme to control cardiovascular diseases during 1972–77 in North Karelia, Brit. Med. J. 4: 1178 – 1183 (1979).

    Article  Google Scholar 

  15. J. T. Salonen, P. Puska, T. E. Kottke, J. Tuomilehto, A. Nissinen, Decline in mortality from coronary heart disease in Finland from 1969–1979, Brit. Med. J. 286: 1857 – 1860 (1983).

    Article  CAS  Google Scholar 

  16. Multiple Risk Factor Intervention Trial, JAMA 248: 1465 – 1468 (1982).

    Article  Google Scholar 

  17. Report of a WHO Expert Committee, Prevention of coronary heart disease, World Health Organisation Technical Report Series 678 (1982)

    Google Scholar 

  18. A. Keys, J. T. Anderson, and F. Grande, Serum cholesterol response to changes in the diet. I. Iodine value of dietary fat versus 2S-P, Metabolism 14:747–758; 766 – 775 (1965).

    Article  CAS  Google Scholar 

  19. World Health Organisation, European Collaborative Group, Multifactorial Trial in the Prevention of Coronary Heart Disease. 3. Incidence and Mortality Results, Eur. Heart J. 4: 141 – 147 (1983).

    Google Scholar 

  20. M. Kornitzer, G. DeBacker, M. Dramaix, F. Kittel, C. Thilly, M. Graffar, and K. Vaylsteek, Belgian Heart Disease Prevention Project: Incidence of mortality results, Lancet 1: 1066 – 1070 (1983).

    Article  PubMed  CAS  Google Scholar 

  21. G. Rose, H. D. Tunstall-Pedoe, and R. F. Heller, U. K. Heart Disease Prevention Project: Incidence and mortality results, Lancet 1: 1062 – 1065 (1983).

    Article  PubMed  CAS  Google Scholar 

  22. M. Feinleib and B. M. Rifkind, Changing patterns of cardiovascular disease mortality in the United States, Israel J. Med. Sci. 18: 1098 – 1105 (1982).

    PubMed  CAS  Google Scholar 

  23. L. Wellin, B. Larsson, K. Svardsudd, L. Wilhelmsen, and G. Tibblin, Why is the incidence of ischaemic heart disease in Sweden increasing? Study of men born in 1913 and 1923, Lancet 1: 1087 – 1089 (1983).

    Article  Google Scholar 

  24. L. Alfredsson and A. Ahlbom, Increasing incidence in mortality from myocardial infarction in Stockholm county, Brit. Med. J. 286: 1931 – 1933 (1983).

    CAS  Google Scholar 

  25. U. Goldburt and J. D. Kark, Changing patterns of cardiovascular disease mortality in the United States, Israel J. Med. Sci. 18: 1077 – 1097 (1982).

    Google Scholar 

  26. E. Guberan, Surprising decline of cardiovascular mortality in Switzerland, 1951–56, J. Epidemiol. Comm. Health 33: 114 – 120 (1979).

    Article  CAS  Google Scholar 

  27. I. Hjermann, I. Holme, K. V. Byre, and P. Leren, The effect of diet and smoking intervention on the incidence of coronary heart disease, Lancet 2: 301 – 310 (1981).

    Google Scholar 

  28. Report of the Committee of Principal Investigators, In preparation.

    Google Scholar 

  29. H. O. Perry, R. K. Winkelmann, R. W. P. Achor, and T. J. Kirby, Side effects of triparanol therapy, Am. J. Med. Sci. 244: 556 – 563 (1962).

    Article  Google Scholar 

  30. A. E. Dorr, K. Gunderson, J. C. Schneider, Jr., T. W. Spencer, and W. B. Martin, Colestipol hydrochloride in hypercholesterolaemic patients - effect on serum cholesterol and mortality, J. Chron. Dis. 31: 5 – 14 (1978).

    Article  PubMed  CAS  Google Scholar 

  31. Lipid Research Clinics Program, The Coronary Primary Prevention Trial: Pesign and Implementation, J. Chron. Dis. 32: 609 – 631 (1979).

    Article  Google Scholar 

  32. M. F. Oliver, Risk of correcting the risk of coronary disease and stroke with drugs, New Engl. J. Med. 306: 297 – 298 (1982).

    Article  PubMed  CAS  Google Scholar 

  33. Medical Research Council Working Party on Mild to Moderate Hypertension, Adverse reactions to bendrofluazide and propranolol for the treatment of mild hypertension, Lancet 2: 539 – 543 (1981).

    Google Scholar 

  34. P. K. Whelton, P. Brennan, W. E. Miall, G. Greenberg, B. Subramanian, Thiazide associated cardiac arrhythmias, Circulation 66:Suppl. 2 – 238 (1982).

    Google Scholar 

  35. M. F. Oliver, Poctors and the drug industry, Brit. Med. J. 286: 888 – 889 (1983).

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Cardiovascular Research Unit, University of Edinburgh, Edinburgh, Scotland

    M. F. Oliver

Authors
  1. M. F. Oliver
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. The Wistar Institute of Anatomy and Biology, Philadelphia, Pennsylvania, USA

    David Kritchevsky

  2. West Chester, Pennsylvania, USA

    William L. Holmes

  3. Institute of Pharmacology and Pharmacognosy, University of Milan, Milan, Italy

    Rodolfo Paoletti

Rights and permissions

Reprints and permissions

Copyright information

© 1985 Plenum Press, New York

About this chapter

Cite this chapter

Oliver, M.F. (1985). Strategy, Yield and Risks of Controlling Plasma Lipids in the Primary Prevention of Coronary Heart Disease. In: Kritchevsky, D., Holmes, W.L., Paoletti, R. (eds) Drugs Affecting Lipid Metabolism VIII. Springer, Boston, MA. https://doi.org/10.1007/978-1-4613-2459-1_18

Download citation

  • DOI: https://doi.org/10.1007/978-1-4613-2459-1_18

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4612-9493-1

  • Online ISBN: 978-1-4613-2459-1

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation